Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies

  title={Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies},
  author={Jieqiong Li and Lan Tan and Huifu Wang and Meng-Shan Tan and Lin Tan and Wei Xu and Qing-Fei Zhao and Jun Wang and Teng Jiang and Jin-Tai Yu},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  pages={476 - 484}
  • Jieqiong LiL. Tan Jin-Tai Yu
  • Published 22 May 2015
  • Medicine, Biology, Psychology
  • Journal of Neurology, Neurosurgery & Psychiatry
Objective We sought to identify the risk factors for predicting the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). Methods We searched 6 electronic databases for cohort studies published from January 1966 to March 2015. Eligible studies were required to be relevant to the subject and provide sufficient data for our needs. Results 60 cohort studies with 14 821 participants from 16 countries were included in the meta-analysis. The strongest positive associations… 

Risk Factors of Rapid Cognitive Decline in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

ApoE4, early onset, early appearance of extrapyramidal signs, high education level, and neuropsychiatric conditions might increase the risk of RCD while older age, diabetes, and multidrug therapy were the protective factors for AD.

Risk factors for predicting progression from normal cognition to mild cognitive impairment: protocol for a systematic review and meta-analysis of cohort studies

A systematic review of the risk factors that predict cognitive disruption in individuals based on associations with MCI, using Stata V.15, does not require ethical approval as no primary data are collected.

A pragmatic dementia risk score for patients with mild cognitive impairment in a memory clinic population: Development and validation of a dementia risk score using routinely collected data

The Mild Cognitive Impairment to Dementia Risk (CIDER) score predicted dementia risk with c‐indices of 0.69 (95% confidence interval [CI] 0.66–0.72) and could be used to inform clinicians and patients about the relative probabilities of developing dementia in patients with MCI.

[Progression of Mild Cognitive Impairment to Dementia of Patients in German Primary Care Practices: A Retrospective Database Analysis].

Age but not sex or type of health insurance was associated with this higher risk of dementia in patients in German primary-care practices, and about one out of four patients developed dementia in the five years following MCI diagnosis.

Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid

Possibility of underlying AD pathology and increased dementia risk should not be ruled out among MCI patients with CSF Aβ42 within the normal range and personalized risk prediction tools incorporating continuous biomarkers may be preferable among individuals with intermediate risk.

Alzheimer’s Disease: Epidemiology and Clinical Progression

Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced and NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making.

Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease

PHS improved the prediction of change in the Clinical Dementia Rating—Sum of Boxes (CDR-SB) score and MMSE over 36 months in patients with MCI at baseline, beyond both APOE and baseline levels of brain atrophy.

APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.

This study shows that the APOEɛ4-TOMM40' 523 haplotype is associated with a higher risk and shorter times of conversion from MCI to AD, possibly driven by CSF biomarkers and mitochondrial dysfunction.

Predictors That a Diagnosis of Mild Cognitive Impairment Will Remain Stable 3 Years Later

Of the protective factors that were identified from demographic, functional, and cognitive data, the absence of apolipoprotein E4 alleles best predicted MCI stability.



Diabetes as a risk factor for dementia and mild cognitive impairment: a meta‐analysis of longitudinal studies

The quantitative meta‐analysis showed that diabetes was a risk factor for incident dementia (including AD, VD and any dementia) and MCI and that subjects with diabetes had higher risk for AD than those without.

Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis

The APOE-ε4 allele is associated with a moderately increased risk for progression from MCI to AD-type dementia, but the low sensitivity and PPV makes genotyping of limited value for predicting AD- type dementia in clinical practice.

MRI and CSF studies in the early diagnosis of Alzheimer's disease

The results show that evaluations of the P‐tau231 level are highly correlated with reductions in the MRI hippocampal volume and by using CSF and MRI measures together one improves the separation of NL and MCI.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD, and atrophy on MRI was detected more consistently than decline on specific cognitive tests/rating scales.

Mild cognitive impairment as a diagnostic entity

  • R. Petersen
  • Psychology, Medicine
    Journal of internal medicine
  • 2004
It is suggested that the diagnosis of mild cognitive impairment can be made in a fashion similar to the clinical diagnoses of dementia and AD, and an algorithm is presented to assist the clinician in identifying subjects and subclassifying them into the various types of MCI.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain and the combination of abnormally low CSF Abeta 42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy.

Current concepts in mild cognitive impairment.

A group of experts on aging and MCI from around the world in the fields of neurology, psychiatry, geriatrics, neuropsychology, neuroimaging, neuropathology, clinical trials, and ethics was convened to summarize the current state of the field of MCI.

Silent brain infarcts and the risk of dementia and cognitive decline.

Elderly people with silent brain infarcts have an increased risk of dementia and a steeper decline in cognitive function than those without such lesions.

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

Findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.

Natural history of mild cognitive impairment in older persons

Mild cognitive impairment is associated with an increased risk of death and incident AD, and a greater rate of decline in selected cognitive abilities.